An Open-label 3×3 Cross-over Study to Compare Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of Single Doses of BMS-986165 in Healthy Volunteers
Latest Information Update: 12 Mar 2020
At a glance
- Drugs Deucravacitinib (Primary) ; Famotidine
- Indications Autoimmune disorders; Crohn's disease; Inflammatory bowel diseases; Liver disorders; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Systemic lupus erythematosus; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 26 Feb 2020 Status changed from recruiting to completed.
- 05 Feb 2020 Status changed from not yet recruiting to recruiting.
- 30 Dec 2019 New trial record